×
ARS Pharmaceuticals Common Stock Net 2020-2024 | SPRY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ARS Pharmaceuticals common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
ARS Pharmaceuticals Common Stock Net 2020-2024 | SPRY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ARS Pharmaceuticals common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.1B
Takeda Pharmaceutical (TAK)
$44.8B
Merck (MKGAF)
$21.8B
Astellas Pharma (ALPMY)
$20.6B
Sandoz Group AG (SDZNY)
$18.4B
Summit Therapeutics (SMMT)
$17B
United Therapeutics (UTHR)
$16.5B
Shionogi (SGIOY)
$12.2B
Neurocrine Biosciences (NBIX)
$12B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Ionis Pharmaceuticals (IONS)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.5B
Corcept Therapeutics (CORT)
$4.9B
Crinetics Pharmaceuticals (CRNX)
$4.7B
Madrigal Pharmaceuticals (MDGL)
$4.7B
Dyne Therapeutics (DYN)
$3.6B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$2B
Harrow (HROW)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
NewAmsterdam Pharma (NAMS)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.5B